Researchers exploring tissue repair and pain relief have several peptide options. Understanding how ARA-290 compares to alternatives like BPC-157 and TB-500 helps with protocol planning.
This comparison does not assign a generated winner or score.
ARA-290 differs from erythropoietin because it is designed as a non-erythropoietic peptide that targets tissue-protective signaling rather than red blood cell production [1] [7]. …
View details →BPC-157, a 15-amino acid peptide derived from human gastric juice, has robust preclinical evidence for musculoskeletal repair, particularly tendons and ligaments. It also shows ne…
View details →TB-500, a synthetic version of thymosin beta-4's active fragment, promotes tissue regeneration through effects on cell migration and angiogenesis. It works more systemically than …
View details →ARA-290 Injection site reactions, fatigue Immune modulation effects BPC-157 Nausea, dizziness Potential renal effects (rare) Thymosin Beta-4 Mild headaches, nausea Allergic reacti…
View details →Primary Mechanism CD131 innate repair receptor activation EPO-R homodimer activation (hematopoietic + tissue repair) Proposed FAK/VEGF pathway modulation ARA-290 offers tissue rep…
View details →Amino Acid Length 11 residues 165 residues 165 residues + modified glycosylation ARA 290 is a fragment, not a full protein Molecular Weight ~1.3 kDa ~30 kDa ~37 kDa ARA 290 is 25×…
View details →